By Rob Camp Last year's pipeline report was warm, starry eyed and exuberant. How wrong can one guy be? Blow 1: The close of the year 2003 saw the "on-hold"-ing of SCH-C, the entry inhibitor that was moribund before the…
Against the Odds, Immune-Based Therapies for HIV Slog Along By Richard Jefferys Industry "Leery" Despite more than two decades of research, there is as yet no approved immune-based therapy (IBT) for HIV infection. And while antiretrovirals continue to course through…
By Richard Stern 12 December, 2003 Dear Friends: In response to my letter regarding the Toronto International AIDS conference, now scheduled for 2006, I have received the following letter from a person living with HIV/AIDS (PLWA) in Jamaica who wishes…
Activists Interrupt Vice Minister of Health at Inauguration Ceremony "We are not here to celebrate World AIDS Day. We are here because this is a day of mourning for us. Our friends continue to die because our government will not…
Activist Meeting With FDA Drugs Division Sets Broad Agenda for Change By Rob Camp Counting Our Blessings The night before the FDA meeting on 14 November 2003, twenty-five of your favorite activists at-large were putting together the game plan of…
Pointers and Prerogatives From and for the Unrepentant Problem Patient By Carlton Hogan Remembering Carlton "AIDS, when you come right down to it, is about loss. Health, life, mobility, financial security, independence, appearance, dreams: Virtually everything is eventually taken away…
by Rob Camp January: starts as new TAG's Antiviral Project Director. Rob and Mark to Houston for ATAC structure meeting to develop stronger national coalition, then to D.C. for Federal AIDS Policy Partnership meeting. Talk of coming assault on Medicaid…
Expediency, Cost-Cutting Trump Science in Peg-Intron Clinical Development Plan By Tracy Swan The Head-to-Head That Wasn't In October of 2003, Schering-Plough held a meeting with HCV and HIV/HCV advocates where they announced a "new" Schering -- one that prioritizes earning…
Glaxo Makes Aggressive Push Into Protease Market With New and Improved Amprenavir By Rob Camp and Heidi Nass Fall Harvest: Bumper Crop of New Drug Approvals in 2003 Drug Novel Mechanism? T-20 Yes atazanavir No FTC (emtricitabine) No fosamprenavir No…
What a Difference a Nucleotide Makes -- Plus IL-15's Role Is STI Outcomes By Richard Jefferys Vif Inhibitors, Anyone? It has been known for some time that an HIV protein called Vif suppresses a human cellular protein that can block…